Pacira BioSciences to Present 3-Year Safety and Efficacy Data of PCRX-201 Following Single Intra-Articular Injection for Moderate-to-Severe Knee Osteoarthritis
Pacira BioSciences to Present 3-Year Safety and Efficacy Data of PCRX-201 Following Single Intra-Articular Injection for Moderate-to-Severe Knee Osteoarthritis
Pacira BioSciences (NASDAQ: PCRX) announced it will present new 3-year data from its ongoing Phase 1 study of PCRX-201 (enekinragene inzadenovec) at the 2025 EULAR Annual Congress in Barcelona. The presentation will focus on safety and efficacy data of this gene therapy candidate following a single intra-articular injection for moderate-to-severe knee osteoarthritis. The presentation titled "A Single Intra-articular Injection of the Gene Therapy PCRX-201 Was Safe and Provided Sustained Clinical Benefits for Patients With Moderate-to-Severe Knee Osteoarthritis Through 3 Years" will be delivered by Professor Philip G. Conaghan from the University of Leeds on June 11, 2025.
Pacira BioSciences (NASDAQ: PCRX) ha annunciato che presenterà nuovi dati a 3 anni del suo studio di Fase 1 in corso su PCRX-201 (enekinragene inzadenovec) al Congresso Annuale EULAR 2025 a Barcellona. La presentazione si concentrerà sui dati di sicurezza ed efficacia di questo candidato alla terapia genica dopo una singola iniezione intra-articolare per l'osteoartrite del ginocchio da moderata a grave. La relazione, intitolata "Una singola iniezione intra-articolare della terapia genica PCRX-201 è stata sicura e ha fornito benefici clinici duraturi per pazienti con osteoartrite del ginocchio da moderata a grave per 3 anni", sarà tenuta dal Professor Philip G. Conaghan dell'Università di Leeds l'11 giugno 2025.
Pacira BioSciences (NASDAQ: PCRX) anunció que presentará nuevos datos a 3 años de su estudio de Fase 1 en curso sobre PCRX-201 (enekinragene inzadenovec) en el Congreso Anual EULAR 2025 en Barcelona. La presentación se centrará en los datos de seguridad y eficacia de este candidato a terapia génica tras una única inyección intraarticular para la osteoartritis de rodilla de moderada a grave. La ponencia titulada "Una única inyección intraarticular de la terapia génica PCRX-201 fue segura y proporcionó beneficios clínicos sostenidos para pacientes con osteoartritis de rodilla de moderada a grave durante 3 años" será impartida por el Profesor Philip G. Conaghan de la Universidad de Leeds el 11 de junio de 2025.
Pacira BioSciences (NASDAQ: PCRX)는 진행 중인 1상 연구에서 PCRX-201 (enekinragene inzadenovec)의 3년 신규 데이터를 2025년 바르셀로나에서 열리는 EULAR 연례 학회에서 발표할 예정입니다. 이번 발표는 중등도에서 중증 무릎 골관절염 환자에게 단회 관절 내 주사 후 이 유전자 치료 후보물질의 안전성과 효능 데이터를 중심으로 진행됩니다. "단일 관절 내 주사로 투여한 유전자 치료제 PCRX-201이 중등도에서 중증 무릎 골관절염 환자에게 3년간 안전하고 지속적인 임상적 이점을 제공하였다"라는 제목의 발표는 2025년 6월 11일 리즈 대학교의 Philip G. Conaghan 교수가 진행할 예정입니다.
Pacira BioSciences (NASDAQ : PCRX) a annoncé qu'elle présentera de nouvelles données sur 3 ans de son étude de phase 1 en cours sur PCRX-201 (enekinragene inzadenovec) lors du Congrès annuel EULAR 2025 à Barcelone. La présentation portera sur les données de sécurité et d'efficacité de ce candidat thérapie génique après une injection intra-articulaire unique pour l'arthrose du genou modérée à sévère. La présentation intitulée « Une injection intra-articulaire unique de la thérapie génique PCRX-201 était sûre et a apporté des bénéfices cliniques durables aux patients atteints d'arthrose modérée à sévère du genou pendant 3 ans » sera donnée par le professeur Philip G. Conaghan de l'Université de Leeds le 11 juin 2025.
Pacira BioSciences (NASDAQ: PCRX) kündigte an, dass es neue 3-Jahres-Daten aus seiner laufenden Phase-1-Studie zu PCRX-201 (enekinragene inzadenovec) auf dem EULAR Jahreskongress 2025 in Barcelona vorstellen wird. Die Präsentation konzentriert sich auf Sicherheits- und Wirksamkeitsdaten dieses Gentherapie-Kandidaten nach einer einmaligen intraartikulären Injektion bei mittelschwerer bis schwerer Kniearthrose. Die Präsentation mit dem Titel „Eine einmalige intraartikuläre Injektion der Gentherapie PCRX-201 war sicher und lieferte anhaltende klinische Vorteile für Patienten mit mittelschwerer bis schwerer Kniearthrose über 3 Jahre“ wird am 11. Juni 2025 von Professor Philip G. Conaghan von der Universität Leeds gehalten.
Positive
None.
Negative
None.
-- Data will be featured at EULAR Annual Congress –
BRISBANE, Calif., May 06, 2025 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ: PCRX), the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform the lives of patients, today announced new data from its ongoing Phase 1 study of its gene therapy candidate PCRX-201 (enekinragene inzadenovec). The data is being presented at the 2025 European Alliance of Associations for Rheumatology (EULAR) Annual Congress, taking place from June 11-14, in Barcelona, Spain.
Presentation Title: A Single Intra-articular Injection of the Gene Therapy PCRX-201 Was Safe and Provided Sustained Clinical Benefits for Patients With Moderate-to-Severe Knee Osteoarthritis Through 3 Years
Presented By: Philip G. Conaghan, MB BS, PhD, FRACP, FRCP, Professor of Musculoskeletal Medicine, University of Leeds, UK; Director, NIHR Leeds Biomedical Research Centre
Date & Time: Wednesday, June 11 from 3:30 pm – 4:30 pm CEST
About PCRX-201 (enekinragene inzadenovec)
PCRX-201 (enekinragene inzadenovec) features an innovative design based on the company’s proprietary high-capacity adenovirus vector platform. It is currently being studied in the fundamental, underlying chronic inflammatory processes that contribute to “wear and tear” over time in osteoarthritis of the knee, a condition that affects more than 14 million individuals in the U.S. today.
In November 2024, Pacira reported promising data from a large Phase 1 study in which PCRX-201 provided sustained improvements in knee pain, stiffness, and function through two years following local administration, with a well-tolerated safety profile. PCRX-201 has received Regenerative Medicine Advanced Therapy (RMAT) designation from the U.S. Food and Drug Administration and Advanced Therapy Medicinal Products (ATMP) designation from the European Medicines Agency. PCRX-201 is the first gene therapy to achieve these clinical results and earn these regulatory designations in osteoarthritis of the knee – a testament to its promise and potential.
Given the promising Phase 1 results, dosing is underway in a Phase 2 study of PCRX-201 (the ASCEND study) for the treatment of knee osteoarthritis. To learn more about PCRX-201 and the company’s clinical development program, please visit the investor events section of the company’s investor website.
About Pacira
Pacira delivers innovative, non-opioid pain therapies to transform the lives of patients. Pacira has three commercial-stage non-opioid treatments: EXPAREL® (bupivacaine liposome injectable suspension), a long-acting local analgesic currently approved for infiltration, fascial plane block, and as an interscalene brachial plexus nerve block, an adductor canal nerve block, and a sciatic nerve block in the popliteal fossa for postsurgical pain management; ZILRETTA® (triamcinolone acetonide extended-release injectable suspension), an extended-release, intra-articular injection indicated for the management of osteoarthritis knee pain; and iovera®º, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. The Company is also advancing the development of PCRX-201 (enekinragene inzadenovec), a novel, locally administered gene therapy with the potential to treat large prevalent diseases like osteoarthritis. To learn more about Pacira, visit www.pacira.com.
Investor Contact:
Susan Mesco, (973) 451-4030
susan.mesco@pacira.com
Media Contact:
Sara Marino, (973) 370-5430
sara.marino@pacira.com
FAQ
What will Pacira BioSciences (PCRX) present at the 2025 EULAR Congress?
Pacira BioSciences will present 3-year safety and efficacy data of PCRX-201 gene therapy for moderate-to-severe knee osteoarthritis following a single intra-articular injection.
Who will present the PCRX-201 data at the 2025 EULAR Congress?
Professor Philip G. Conaghan from the University of Leeds will present the data on June 11, 2025, from 3:30 pm to 4:30 pm CEST.
What is PCRX-201 being developed for?
PCRX-201 (enekinragene inzadenovec) is being developed as a gene therapy for treating moderate-to-severe knee osteoarthritis.
When and where will the PCRX-201 data be presented?
The data will be presented at the 2025 European Alliance of Associations for Rheumatology (EULAR) Annual Congress in Barcelona, Spain, taking place from June 11-14, 2025.
An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
